Distinguish hypotheses, evidence and human validation.
Practical CNS medicines through disciplined science.
Telesti exists to develop CNS medicines that are both scientifically differentiated and practical to deliver.
Ambitious therapeutic design. Explicit decision standards.
We combine medicinal chemistry and CNS development strategy with an operating model that asks a simple question at every stage: what evidence is required to advance, redesign or stop?
This approach is intended to preserve scientific ambition while preventing weak assumptions from compounding into expensive development commitments.
Four commitments.
Trace material claims to controlled data and independent confirmation.
Fund to objective checkpoints with protected contingency.
Evaluate practical delivery and safety alongside mechanism.
Chemistry and execution.

Uroš Laban, PhD
Uroš leads medicinal chemistry and scientific strategy. His background includes CNS drug discovery, structure–activity relationship development and the design of next-generation serotonergic compounds.

Graham Pilger
Graham leads company strategy, financing, partnerships and program execution. His background spans psychiatry research, early-stage healthcare ventures and operational leadership across emerging therapeutic modalities.
Biographies and credentials should receive final individual and company approval before production launch.
Built in a growing life-sciences and technology ecosystem.
Telesti operates from Austin and works with a distributed network of scientific, regulatory, legal and development collaborators.
Advisors and collaborators are named publicly only after written consent and verification of titles and affiliations.
Exceptional scientists and operators are welcome.
We welcome targeted expressions of interest from people aligned with rigorous CNS development and stage-gated execution.